louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00689650: Fractional Nonablative 1540 nm Laser Resurfacing for Burn Scars- A Randomised Controlled Trial
Official title: Fractional Nonablative 1540 nm Laser Resurfacing for Burn Scars- A Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Burn Scar Patients
Lead sponsor: Bispebjerg Hospital
Sponsor class: OTHER
First posted: 2008-06-03
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no

Brief summary: The objective was to evaluate the efficacy of 1540 nm fractional laser treatment of mature burn scars.


Eligibility criteria: Inclusion Criteria:

* Burn scars with and without previous skin grafting.

Exclusion Criteria:

* A tendency to produce hypertrophic scars or keloids,
* Previous treatment with dermabrasio, chemical peel, filler, laser treatment or Intense Pulsed Light (IPL) of study areas,
* Photosensitivity,
* Pregnancy or lactation,
* Current anticoagulative medication,
* Oral retinoid drugs within the past 6 months,
* Pigmentation after recent exposure to sun or solarium,
* Patients not considered to be able to follow the treatment protocol.

Primary outcomes:
measure: Change of skin texture from baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen NV
country: Denmark
facility: Bispebjerg University Hospital
Study officials:
References:
Clinical trial NCT06976450: Evaluating the Effectiveness of ChemoNurs: A Mobile Chemotherapy Drug Guide for Oncology Nurses
Official title: Evaluating the Effectiveness of ChemoNurs: A Mobile Chemotherapy Drug Guide for Oncology Nurses - A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chemotherapy
Lead sponsor: Koç University
Sponsor class: OTHER
Collaborators: name: The Scientific and Technological Research Council of Turkey
First posted: 2025-05-16
Enrollment: 59
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study aimed to evaluate the effectiveness of a mobile chemotherapy drug guide application, ChemoNurs, developed for oncology nurses, in improving their knowledge and attitudes toward chemotherapy practices.

H1: The mobile chemotherapy drug guide developed for oncology nurses increases their knowledge related to chemotherapy.

H2: The mobile chemotherapy drug guide developed for oncology nurses promotes the development of positive attitudes toward chemotherapy.

H3: The mobile chemotherapy drug guide developed for oncology nurses increases their satisfaction.


Eligibility criteria: Inclusion Criteria:

* Actively administering chemotherapy treatments
* Having knowledge of how to use an Android or iOS smartphone
* Possessing mobile literacy
* Working in oncology clinics for a duration of 0-12 months
* Volunteering to participate in the study

Exclusion Criteria:

* Not having completed the orientation process in oncology clinics
* Not having administered chemotherapy
* Incomplete responses in the data collection forms
* Willingness to withdraw at any stage of the study
* Participation in the Oncology Nursing Certification Program
* Prior attendance in courses or training sessions related to chemotherapy drugs

Primary outcomes:
measure: Change in Chemotherapy Knowledge Score
timeFrame: Baseline (Month 0), Midpoint (Month 3), and Endpoint (Month 6)
measure: Change in Attitudes Toward Chemotherapy Practices
timeFrame: Baseline (Month 0), Midpoint (Month 3), and Endpoint (Month 6)
Secondary outcomes:
measure: Mobile Application Usability
timeFrame: Month 3 and Month 6
measure: Nurses' Satisfaction with CHEMONURS Application
timeFrame: Month 6
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Hacettepe University Oncology Hospital
state: Altındağ
Study officials:
affiliation: Koç University
name: Remziye Semerci Şahin, Assistant professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT04574050: SELF-BREATHE RCT for Chronic Breathlessness
Official title: A Self - Guided, Internet - Based Intervention for Patients With Chronic Breathlessness (SELF-BREATHE): Feasibility Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cancer
COPD
Asthma
Bronchiectasis Adult
Interstitial Lung Disease
Cystic Fibrosis
Chronic Heart Failure
Sickle Cell Disease
Renal Failure
Liver Failure
Post COVID-19
Dyspnea
Lead sponsor: King's College Hospital NHS Trust
Sponsor class: OTHER
Collaborators: name: King's College London
First posted: 2020-10-05
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: A feasibility RCT comprising two groups:

1. Intervention (SELF-BREATHE in addition to standard NHS care)
2. Control group (standard / currently available NHS care)
Primary purpose: TREATMENT

Brief summary: A feasibility RCT comprising two groups:

1. Intervention (SELF-BREATHE in addition to standard NHS care)
2. Control group (standard / currently available NHS care)


Eligibility criteria: Inclusion Criteria:

* Adults ≥ 18 years of age, with the ability to read and type in English
* Access to a computer, or tablet or smart phone, with internet access and the ability to email
* Chronic breathlessness (CB) defined as; breathlessness that persists (\>3months) despite optimal pharmacological treatment of the underlying disease including cancer, chronic obstructive pulmonary disease (COPD),asthma, interstitial lung disease (ILD), bronchiectasis, cystic fibrosis (CF) chronic heart failure (CHF), sickle cell disease, chronic renal/ liver failure or post COVID-19
* Chronic breathlessness at rest or on exertion; MRC dysponea score \>2
* Willing to engage with short-term self-guided internet-based breathlessness intervention (SELF-BREATHE)
* Able to provide informed consent

Exclusion Criteria:

* Breathlessness of unknown cause
* A primary diagnosis of chronic hyperventilation syndrome
* Currently participating in a rehabilitation programme, e.g. pulmonary/cardiac rehabilitation

Primary outcomes:
measure: Feasibility: the number of patients recruited into this study over a 12-month period
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: King's College Hospital NHS Foundation TRUST
Study officials:
References:
Clinical trial NCT02078050: Volontary Inspiratory Muscles Measures Compared With Phrenic Nerves Magnetic Stimulations Measures
Official title: Volontary Inspiratory Muscles Measures Compared With Phrenic Nerves Magnetic Stimulations Measures
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Neuromuscular Diseases
Respiratory Failure
Lead sponsor: Centre d'Investigation Clinique et Technologique 805
Sponsor class: OTHER
First posted: 2014-03-05
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: Respiratory failure is the main death cause in neuromuscular diseases. Non-invasive and volitional measures of inspiratory muscles strength include the nasal pressure with an occluded nostril (Psnip) and the maximal inspiratory pressure (PImax). Unfortunately, volitional maneuvers depend of patient effort. The aim of this research is to validate a non-invasive and non-volitional technique to evaluate diaphragm strength at neuromuscular diseases patients. The methodology consists to add to PImax and Psnip measures 5 phrenic nerves magnetical stimulation maneuvers (Pstim).Stimulations will be realize at 3 inspiratory pression levels (0, -1 cm H2O and -5 cm H2O).


Eligibility criteria: Inclusion Criteria:

* 18 years old and more men or women
* neuromuscular diseases
* Pimax and Snip evaluation Indication

Exclusion Criteria:

* pregnant women
* Usual contre-indications for nuclear magnetic resonance

Primary outcomes:
measure: Magnetic stimulation pressure measure (Pstim), according to 3 conditions : Pstime, Pstim-5 and Pstim-1 (measured in cmH20). The condition which is most correlated with maximal inspiratory pressure (Pimax or Psnip) is selected.
timeFrame: 10 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Garches
country: France
facility: Hopital R. Poincaré
Study officials:
References:
Clinical trial NCT04418050: Prosthetic Arthroplasties in Weight-bearing Shoulders
Official title: Prosthetic Arthroplasties in Weight-bearing Shoulders in Individuals With Long-term Wheelchair Use
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prosthetic Arthroplasties
Keywords: paraplegia
Shoulder prosthesis
spinal cord injury
wheelchair
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2020-06-05
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients not walking or rarely walking, long-term users of a wheelchair

Brief summary: Repeated transfers and wheelchair propulsion in patients with neurological deficit of the lower limbs leads to a major mechanical overload of the upper limbs, especially on shoulders, the "weight-bearing" shoulder. Under these conditions, arthroplasty is subject to significant constraints; such an indication in this condition is always discussed. The objective of this study was to evaluate the medium-term clinical and functional outcomes of anatomical and reverse arthroplasty on the weight-bearing shoulder in individuals with long-term wheelchair use.


Eligibility criteria: Inclusion criteria:

* patients not walking or rarely walking, long-term users of a wheelchair before the intervention, and surgery on at least one shoulder by anatomical or reverse prosthesis

Exclusion criteria:

* Patient walking without aid
* Shoulder surgery other than arthroplasty

Primary outcomes:
measure: Evolution of joint mobility
timeFrame: 1 day
Secondary outcomes:
measure: number of searches for early implant loosening
timeFrame: 1 day
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Uhmontpellier
Study officials:
affiliation: University Hospital, Montpellier
name: Léo Chiche, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06127550: taVNS for Letter Learning in Dyslexia
Official title: Effect of Non-invasive Vagus Nerve Stimulation on Letter Learning in Dyslexia
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Dyslexia
Lead sponsor: University of Florida
Sponsor class: OTHER
First posted: 2023-11-13
Enrollment: 100
Sex: ALL
Minimum age (years): 10
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants will be randomly assigned to either active stimulation or sham stimulation groups.
Primary purpose: BASIC_SCIENCE

Brief summary: This is a pilot study to establish feasibility of transcutaneous auricular vagus nerve stimulation (taVNS) for improving letter-learning in adolescents with dyslexia. The main goals of the study are to 1) evaluate whether children in this age range will tolerate low level stimulation over the course of multiple sessions, 2) determine whether low level taVNS improves novel letter learning in dyslexia, and 3) evaluate the effect of low level taVNS on the brain's response to letters. Participants will complete fMRI before training, immediately after training, and a few weeks after training ends. Training will consist of six 30-minute lessons during which participants will learn novel letter-sound relationships while receiving either active or sham taVNS. Researchers will compare stimulation conditions to determine effect of this device on learning and neural plasticity.


Eligibility criteria: Inclusion Criteria:

* Normal non-verbal IQ
* Reading scores above 90 on four single word reading measures (typical reader) OR reading scores below 90 on two or more single word reading measures (dyslexia) with or without ADHD

Exclusion Criteria:

* Neurological diagnoses (e.g., autism, epilepsy, etc.)
* Medications other than those prescribed for ADHD
* Nonverbal IQ below 80

Primary outcomes:
measure: Adverse events
timeFrame: 4 weeks
measure: Compliance
timeFrame: 4 weeks
Secondary outcomes:
measure: Letter ID
timeFrame: 6 weeks
measure: Decoding
timeFrame: 6 weeks
measure: Automaticity
timeFrame: 6 weeks
Other outcomes:
measure: fMRI
timeFrame: 6 weeks
Locations:
city: Gainesville
country: United States
facility: University of Florida
state: Florida
Study officials:
References:
Clinical trial NCT05929950: The Role of Autoimmunity and Obesity in Polycystic Ovary Syndrome
Official title: The Role of Autoimmunity and Obesity in Polycystic Ovary Syndrome
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Polycystic Ovary Syndrome
Keywords: autoimmunity
obesity
Polycystic ovary syndrome
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2023-07-03
Enrollment: 90
Sex: FEMALE
Minimum age (years): 12
Maximum age (years): 55
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: women

Brief summary: The goal of the study is to detect autoantibodies in the serum of the women with PCOS and evaluate the obesity markers to investigate the the role of autoimmunity and obesity in PCOS


Eligibility criteria: Inclusion Criteria:

* patients diagnosed with PCOS according to the Rotterdam (2003) criteria.

Exclusion Criteria:

* Patients with other causes of hyperandrogenism as congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome, hyperprolactinemia, virilizing ovarian or adrenal tumors and those taking drugs affecting insulin resistance, such as estrogens, oral contraceptives and corticosteroids during the previous three months before the study.

Primary outcomes:
measure: measuring serum anti-ovarian, anti-nuclear, anti-double stranded and anti-thyroid antibodies
timeFrame: 3 months after recruitment
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag university
Study officials:
References:
Clinical trial NCT02217150: The STAR Prospective Clinical Series
Official title: The DFINE STAR™ Tumor Ablation Prospective Clinical Series
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Metastasis to Vertebral Column
Lead sponsor: Merit Medical Systems, Inc.
Sponsor class: INDUSTRY
First posted: 2014-08-15
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects with painful spinal metastases following t-RFA with the STAR™ Tumor Ablation System.

Brief summary: Prospective clinical series to gather post tumor ablation clinical outcomes from subjects with painful spinal metastases following targeted radiofrequency ablation (t-RFA) treatment with the STAR™ Tumor Ablation System.


Eligibility criteria: Inclusion Criteria:

* The STAR™ Tumor Ablation System is indicated for palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body.

Exclusion Criteria:

* The device is contraindicated in subjects with heart pacemakers, or other electronic device implants.
* The device is contraindicated in vertebral body levels C1-7.

Primary outcomes:
measure: Change in Pain
timeFrame: 1 month
Secondary outcomes:
measure: Change in Quality of Life
timeFrame: 3 months
measure: Change if Quality of Life
timeFrame: 3 months
measure: Change in Function
timeFrame: 3 months
Other outcomes:
Locations:
city: Escondido
country: United States
facility: Palomar Pomerado Health System
state: California
city: Los Angeles
country: United States
facility: University of Southern California
state: California
city: Kansas City
country: United States
facility: University of Kansas Medical Center
state: Kansas
city: Bethesda
country: United States
facility: Suburban Hospital
state: Maryland
city: Austin
country: United States
facility: Austin Radiological Associates
state: Texas
city: Salt Lake City
country: United States
facility: St. Mark's Hospital
state: Utah
city: Alexandria
country: United States
facility: Inova Alexandria Hospital
state: Virginia
city: Spokane
country: United States
facility: Providence Sacred Heart Hospital
state: Washington
Study officials:
affiliation: Inova Alexandria Hospital
name: Sandeep Bagla, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00622050: The Relationship of TV Viewing to Energy Balance in Adults
Official title: The Effects of Limiting TV Viewing on Diet, Exercise, and Sleep in Overweight and Obese Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Overweight
Lead sponsor: University of Vermont
Sponsor class: OTHER
Collaborators: name: United States Department of Agriculture (USDA)
First posted: 2008-02-22
Enrollment: 44
Sex: ALL
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The specific objectives of this project are to:

1. Investigate the effects of reducing TV viewing time on energy intake, eating behavior, and energy expenditure in overweight or obese adult subjects, thus providing a basis for evaluating if reducing TV viewing time might be a useful adjunct therapy in obesity prevention and treatment
2. Analyze the types of foods eaten in conjunction with TV viewing
3. Determine if there is an association between location of TV and BMI.


Eligibility criteria: Inclusion Criteria:

* BMI between 25-50
* Watch at least 3 hours of TV per day or 21 hours per week.
* Between the ages of 21-65 years.
* Willing to have study staff enter home several times.
* Willing to have TV viewing time reduced.

Exclusion Criteria:

* Live greater than 45 minutes from UVM campus.
* Enrolled in a weight loss study
* Pregnant or planning to become pregnant during active study protocol.
* Breastfeeding for 6 months or less.

Primary outcomes:
measure: Energy Intake
timeFrame: Phase I and Phase II
Secondary outcomes:
measure: Energy expenditure
timeFrame: Phase I and Phase II
Other outcomes:
Locations:
city: Burlington
country: United States
facility: UVM Department of Nutrition and Food Sciences
state: Vermont
Study officials:
References:
citation: Otten JJ, Jones KE, Littenberg B, Harvey-Berino J. Effects of television viewing reduction on energy intake and expenditure in overweight and obese adults: a randomized controlled trial. Arch Intern Med. 2009 Dec 14;169(22):2109-15. doi: 10.1001/archinternmed.2009.430.
citation: Otten JJ, Littenberg B, Harvey-Berino JR. Relationship between self-report and an objective measure of television-viewing time in adults. Obesity (Silver Spring). 2010 Jun;18(6):1273-5. doi: 10.1038/oby.2009.371. Epub 2009 Oct 29.
Clinical trial NCT01395550: Secondary Prevention Treatment in Patients Who Have Suffered a Cardiovascular Event
Official title: Secondary Prevention Treatment in Patients Who Have Suffered a Cardiovascular Event.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiovascular Events
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2011-07-15
Enrollment: 88
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with cardiovascular events

Brief summary: AstraZeneca was interested in knowing how Cardiologists and Physicians treat patients who have suffered a cardiovascular event.


Eligibility criteria: Inclusion Criteria:

* All patients who has experienced cardiovascular events

Exclusion Criteria:

* Patients with no cardiovascular events.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01052350: PET Imaging in Parkinson Disease Dementia
Official title: Investigations of Dementia in Parkinson Disease
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Parkinson's Disease
Keywords: Parkinson disease
PET imaging
PIB
dementia
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
First posted: 2010-01-20
Enrollment: 320
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants with and without Parkinson disease will be recruited from the Movement Disorders Center at Washington University, the St. Louis metro area, and throughout the midwest region.

Brief summary: The purpose of this study is to use a brain imaging method called PIB PET to determine dementia subtypes in patients with Parkinson's disease. The ultimate goal of this project is to be able to identify individuals with PD who are at risk of developing dementia, and to distinguish the underlying cause of dementia.

Detailed description: The purpose of this study is to use a brain imaging method called PIB PET to determine dementia subtypes in patients with Parkinson's disease. The ultimate goal of this project is to be able to identify individuals with PD who are at risk of developing dementia, and to distinguish the underlying cause of dementia. We will be including both PD and normal subjects in this study. This a long term study and we are considering including a total of 320 participants in this protocol.

Eligibility criteria: Inclusion Criteria:

* PD patients must exhibit three of the following cardinal signs: rest tremor, rigidity, bradykinesia, or postural instability; or two of these features with one of the first three displaying asymmetry.

Exclusion Criteria:

* history of head trauma, major neurological or psychiatric diseases other than Parkinson disease and dementia, e.g. stroke, multiple sclerosis, depression or schizophrenia
* severe systemic diseases
* inability to lie still for 90 minutes
* metallic implants, pacemakers, or any other contraindication to MRI
* refusal to consent to brain donation

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Saint Louis
country: United States
facility: NeuroClinical Research Unit (NCRU), Washington University School of Medicine
state: Missouri
Study officials:
affiliation: Washington University School of Medicine
name: Joel S. Perlmutter, MD
role: PRINCIPAL_INVESTIGATOR
References: